Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus

Inclusion Criteria: 1. Subject is \> 18 years old 2. Presence of one or more de novo stenosis equal or greater than 70% in a native coronary artery, treated with a second generation drug-eluting stent 3. Subject and the treating physician agree that the subject will comply with all follow-up evaluations 4. Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site Exclusion Criteria: 1. Subject's age is \< 18 years and with acute myocardial infarction in the 48 prior to the procedure 2. The patient is pregnant or breastfeeding 3. Known allergies to: aspirin, clopidogrel (Plavix) and ticlopidine (tiklid), heparin, Paclitaxel, Everolimus, ABT 578, stainless steel, or contrast agent (which cannot be adequately pre-medicated) 4. A platelet count \< 75,000 cells/mm3 or \> 700,000 cells/mm3 or a WBC \< 3,000 cells/mm3 5. Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints 6. Prior participation in this study 7. Active peptic ulcer or upper GI bleeding within the prior 3 months 8. Subject has active sepsis 9. Any lesion that is located in a saphenous vein graft 10. In the investigator's opinion, subject has a co-morbid condition(s) that could limit the life expectancy to less than one year, or limit the subject's ability to participate in the study or comply with follow-up requirements or impact the scientific integrity of the study